Trial Profile
Predictive factors of pathologic response towards trastuzumab as neoadjuvant chemotherapy in HER2-positive breast cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Advanced breast cancer; Breast cancer; HER2 positive breast cancer
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 13 Oct 2014 New trial record